Actively Recruiting
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal Infections
Led by Peter MacCallum Cancer Centre, Australia · Updated on 2025-09-05
10
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new imaging technique to detect invasive Aspergillus fungal infections using a radiolabelled fungal component called a siderophore. This open-label, single-center pilot study aims to show how a gallium-siderophore tracer accumulates in areas of proven or probable invasive fungal infection. The study will also assess how safe and tolerable this imaging method is for patients. Participants will receive a whole-body PET/CT scan using the 68Ga-labelled TAFC tracer. The study plans to recruit 10 patients diagnosed within the last two weeks with proven or probable invasive fungal infection. The imaging will be done to observe uptake of the tracer at infection sites, with follow-up assessments scheduled over the study period. During the study, patients will undergo PET/CT scans and have their physiological biodistribution evaluated up to three hours after injection of the radiotracer. Safety assessments will be made within 24 hours after the scan. The imaging findings will also be compared to standard CT and FDG-PET/CT scans. Participants will be monitored according to the study protocol, including scheduled visits and follow-up to assess outcomes.
CONDITIONS
Brief Title
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient has provided written informed consent
- Aged 18 years or older at written informed consent
- Within 2 weeks of proven, probable, or possible invasive fungal infection diagnosis as per EORTC criteria
- Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter
- Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up
You will not qualify if you...
- Women who are pregnant or lactating
- Iron infusion within one week prior to scan
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 hours on scan day
Participants undergo a 68Ga-labelled TAFC PET/CT scan to evaluate uptake of the radiolabelled siderophore and assess safety and bio distribution.
1 visit (in-person)
Duration - Up to 24 hours after scan
Participants are observed for safety and tolerability following the imaging procedure.
Trial Site Locations
Total: 1 location
1
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Actively Recruiting
Research Team
A
Abby Douglas
B
Beatrice Sim
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here